Reactivity of lymphocytes from primary neoplasms of lymphoid tissues.
Proliferative responses by blood and tumor lymphocytes to plant mitogens and allogeneic leukocyte antigens were tested concomitantly on 12 patients with Hodgkin's disease, 10 with chronic lymphocytic leukemia, and seven with non-Hodgkin's lymphomas. In 13 control studies, 3H-thymidine incorporation by blood and lymph node lymphocytes was brisk and, overall, comparable. With Hodgkin's disease, where extent of disease involvement and lymphocyte-depleted tumor histology were factors in the degree of responsiveness, incorporation was higher or at least comparable by tumor lymphocytes when compared with incorporation by autologous blood lymphocytes. Lymph node lymphocytes, especially with clinically stable disease, were more responsive than blood lymphocytes with chronic lymphocytic leukemia. Conversely, tumor lymphocytes were hyporesponsive compared with autologous blood lymphocytes with non-Hodgkin's lymphomas, where prognosis is usually less favorable than with chronic lymphocytic leukemia. Plasma from four out of 33 patients, although not lymphocytotoxic, inhibited lymphoproliferative responses.
D006689:Hodgkin Disease / Q000097:blood / Q000276:immunology; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology; D008934:Mitogens / Q000494:pharmacology; D009000:Monocytes / Q000276:immunology
D008934:Mitogens